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A Randomized Trial and the 
Treatment of Pemphigus Vulgaris
David J. Margolis1
Pemphigus vulgaris is a rare, life-threatening autoimmune disease. 
Mycophenolate mofetil is a potent immunosuppressant medication approved 
by the Food and Drug Administration to be used after solid organ transplanta-
tion and to treat pemphigus vulgaris. Mycophenolate mofetil has not become 
the “wonder drug” that had been anticipated based on initial clinical reports. 
Studies like that reported by Beissert et al. in this issue are essential to improve 
dermatologic care.
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Pemphigus vulgaris is a severe, life-
threatening autoimmune disease asso-
ciated with antibodies to desmoglein 
1 and 3 (Amagi, 2008; Stanley, 2008). 
These antibodies cause blisters that 
originate just above the basal cell layer 
of the epidermis. The science behind 
this association is extensive, elaborate, 
and elegant. The relationship between 
desmoglein antibodies and the clini-
cal phenotype is so profound and 
invest igators’ ability to manipulate and 
study this relationship in culture and 
nonhuman species is so absolute that 
pemphigus vulgaris is often described 
as a “model” autoimmune illness.
Pemphigus vulgaris is rare, however—
its incidence is often estimated to be 0.5 
to 4 per million person-years, and it has 
a point prevalence of 1 to 4 per 100,000 
people (Amagi, 2008; Groves, 2009; 
Marazza et al., 2009; Stanley, 2008). 
The disease was thought to be fatal until 
Lever’s introduction of systemic corti-
costeroid therapy, which has become 
a mainstay of treatment. However, 
most derma tology textbooks now rec-
ommend that, in order to minimize 
side effects, maximize early control 
of the disease, and decrease mortal-
ity, systemic corticosteroid therapy 
should be concurrently augmented 
with an additional immunosuppressive 
agent such as mycophenolate mofetil, 
azathioprine, or cyclophosphamide 
(Amagi, 2008; Groves, 2009; Stanley, 
2008).
About 10 years ago, I heard a pre-
sentation about a patient with pem-
phigus vulgaris. The resident presenter 
was adamant about using a wonder-
ful new treatment, mycophenolate 
mofetil, noting that it was superior to 
sole corticosteroid therapy or the com-
bination of corticosteroid therapy with 
any other agent. I asked about the evi-
dence supporting this therapy and was 
told that current scientific evidence 
made it obvious that this was the cor-
rect approach. Within two years, I was 
told by peers that in treating pemphi-
gus vulgaris it was never proper to use 
a systemic corticosteroid alone, that 
it should always be used with myco-
phenolate mofetil. Furthermore, I was 
told that mycophenolate mofetil was 
essential for sparing patients from side 
effects of systemic corticosteroid ther-
apy and that mycophenolate mofetil 
was an important part of any adequate 
therapeutic regimen. A few years later, I 
spoke to a colleague who was trying to 
develop a randomized clinical trial to 
evaluate pemphigus vulgaris treatment 
regimens. The proposal included the 
randomization of patients with pem-
phigus vulgaris to standard of care 
(corticosteroids) or to standard of care 
plus another agent that was not myco-
phenolate mofetil. The review panel 
was supportive of the study, but indirect 
feedback related to the decision not to 
fund indicated that there was already 
a cure for pemphigus vulgaris—myco-
phenolate mofetil—making the study 
unnecessary.
Mycophenolate mofetil is a po tent 
immuno suppressant medi ca tion app-
roved by the Food and Drug Admin-
istration (FDA) for the prevention of 
solid-organ rejection after trans plantation 
(renal, cardiac, and hepatic). It is an 
inosine monophosphate dehydro-
genase inhibitor (de Jonge et al., 
2009; Physicians’ Desk Reference, 
2009). Therefore, it inhibits guanosine 
nucleotide synthesis, which is 
important for T- and B-cell proliferation 
and function. Mycophenolate mofetil 
has often been used as a substitute for 
azathioprine, and it has been endorsed 
by several authors as an effective as 
well as steroid-sparing agent to treat 
many autoimmune illnesses (de Jonge 
et al., 2009; Villarroel et al., 2009). 
Commonly reported side effects of 
this drug include dizziness, headache, 
nausea, diarrhea, leuko penia, tremors, 
and vomiting (de Jonge et al., 2009; 
Physicians’ Desk Reference, 2009). 
The FDA issued a “black box” warning 
describing concerns about lymphoma, 
malignancy, and infection after use of 
the drug and, more recently, a warning 
about increased risk of opportunistic 
infections such as progressive multi-
focal leukoencephalopathy. Its use 
is also associated with an increased 
risk of pregnancy loss and congenital 
malformations.
The study by Beissert et al. (2010, 
this issue) is a fine example of a ran-
domized clinical trial. Randomized 
clinical trials are often considered the 
best study design for proving the effica-
cy of a therapy. The random treatment 
selection is helpful in controlling treat-
ment selection bias, and other design 
features, such as precise definition of 
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the disease to be studied, longitudinal 
follow-up, a proper understanding of 
drug use/exposure, the proper acquisi-
tion of end points (often by blinding the 
evaluator), adherence to a well-written 
protocol, and statistical analysis plan, 
help to ensure that this type of study 
will provide the highest level of evi-
dence. In fact, the use of this design has 
recently been advocated for basic sci-
ence studies as well (Bart van der Worp 
et al., 2010).
The goal of Beissert et al. (2010) 
was to evaluate the efficacy and safe-
ty of mycophenolate mofetil when 
administered as 2 or 3 g/day in addi-
tion to about 1 mg/kg of corticosteroid 
per day to individuals with pemphigus 
vulgaris. The authors randomized 96 
patients, and 75 completed the study. 
For a disease as rare as pemphigus 
vulgaris, this was a Herculean effort. 
To summarize, the investigators noted 
that after 48 to 52 weeks of follow-up, 
roughly an equal number of subjects 
(any mycophenolate mofetil use, 69%, 
versus corticosteroid use only, 64%, P 
= 0.66) had responded to therapy. In 
contrast, on the basis of historical data, 
the study had been designed assuming 
that 30% of patients receiving only 
corticosteroids would respond versus 
a 70% response rate in the mycophe-
nolate mofetil–plus-corticosteroid 
arm. However, patients who received 
mycophenolate mofetil did respond 
more quickly (by about 7 weeks), had 
more durable responses (lasting about 
3 months longer), and over the course 
of the study used about half a gram less 
corticosteroid (about 10 mg/week less) 
and were maintained on low-dose cor-
ticosteroid (prednisone <10 mg/day) 
almost 2 months longer. With respect 
to safety, there were few differences in 
adverse events, serious adverse events, 
or dropout in subjects who were ran-
domized to receive mycophenolate 
mofetil with corticosteroid versus those 
who received corticosteroid alone.
These fascinating results show that 
the use of mycophenolate mofetil 
may help a patient achieve an earlier, 
more durable response when admin-
istered with corticosteroid therapy as 
compared with corticosteroid therapy 
alone. It is important to note that these 
analyses were not part of the primary 
end point; some would therefore sug-
gest that the findings are more akin to 
the results presented in a cohort study 
than the primary results of a random-
ized clinical trial. In addition, the total 
amount of corticosteroid required to 
achieve this response may be clinically 
similar and the overall rate of adverse 
and serious adverse events may be 
similar to those for patients receiving 
corticosteroid therapy alone. The study 
did not appear to demonstrate the dra-
matic differences that would have been 
expected based on “expert opinion.”
Randomized clinical trials also 
have limitations. As in bench science, 
all studies must be replicated. One 
study never answers all questions, 
and sometimes the results of a single 
study are not reproducible. Although 
randomized clinical trials maximize 
the internal validity of a study (e.g., by 
reducing bias due to treatment selec-
tion or information errors), the external 
validity of a randomized clinical trial 
may be compromised as compared 
with other study designs. External 
validity is related to how well infor-
mation gained from the study general-
izes outside of the study. For example, 
this study had inclusion and exclusion 
criteria that might have rendered the 
study population distinct from a gen-
eral patient population with pemphi-
gus vulgaris, and it used a precise plan 
for tapering corticosteroid. The reader 
needs to decide whether subject selec-
tion and treatment are importantly dif-
ferent from their general practice. In 
addition, were the reported outcomes 
clinically meaningful and not just sta-
tistically meaningful?
Judging by the results presented by 
Beissert et al. (2010), mycophenolate 
mofetil is certainly not the wonder drug 
described to me several years ago, nor 
did it work as well as had been antici-
pated in the investigators’ power analy-
sis, but, to be fair, very few drugs work 
as well as initially discussed by clini-
cians. The results of this study demon-
strate that it is important for physicians 
contemplating the use of mycopheno-
late mofetil to consider carefully the 
benefits and risks of the drug as well 
as its risks when used in combination 
with corticosteroids. It appears that, 
after a year of care, clinical responses 
are similar whether or not mycopheno-
late mofetil is added to corticosteroid 
treatment. What must be considered is 
whether the potential for a quicker and 
more durable response is advantageous 
to patients and whether the steroid-
sparing effect is more important than 
the added risks of using mycophenolate 
mofetil, which include malignancy and 
fatal opportunistic infections. Finally, it 
is essential to consider whether myco-
phenolate mofetil offers an advantage 
over other steroid-sparing agents that 
have not been objectively compared 
with it in a similar randomized clini-
cal trial setting. In fact (again, based 
on limited evidence), another promis-
ing therapy based on rituximab is now 
being championed for the treatment of 
pemphigus vulgaris (Cianchini et al., 
2007).
The pages of this journal are a tes-
tament to the high level of investiga-
tion common to cutaneous science, 
yet dermatologists are often eager to 
accept as effective therapies that have 
not been tested in a well-designed 
clinical study. Reading the JID makes 
me certain that we have a profound 
understanding of keratinocyte biology 
and the biology of many human skin 
diseases, as represented by mouse 
models and cell culture. Unfortunately, 
studies like that of Beissert et al. (2010) 
are uncommon because of our dis-
cipline’s habit of underfunding, and 
seemingly undervaluing, clinical sci-
ence. The investigators are to be con-
gratulated for their effort, the quality of 
their work, and the contribution they 
have made to our understanding of 
clinical dermatologic care.
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Mycophenolate 
mofetil helped 
patients with 
pemphigus achieve 
earlier and more 
durable responses 
when administered 
with corticosteroids.
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Grabbing Amphiregulin  
by the Tail to Better Understand 
Keratinocyte Growth
John T. Seykora1
Amphiregulin (AReG) is an important regulator of cellular growth in keratinocytes, 
carcinomas, and hyperproliferative epidermal disorders, including psoriasis. Stoll 
and colleagues present data suggesting that the cytoplasmic carboxy-terminal 
domain of amphiregulin plays an important role in regulating autocrine keratino-
cyte growth through the epidermal growth factor receptor. These observations 
raise novel and interesting biological questions regarding the function of the cyto-
plasmic c-terminal region of AReG.
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Amphiregulin (AREG), a member of 
the EGFR ligand family, is important for 
regulating keratinocyte growth (Stoll 
et al., 2010, this issue). In vivo studies 
of transgenic mice overexpressing 
AREG in the epidermis demonstrate a 
complex yet psoriasiform phenotype 
including epidermal hyperplasia, cuta-
neous inflammation, and arthritis (Cook 
et al., 1997). Ligand-dependent signaling 
through EGFR in keratinocytes is com-
plex, because these cells can produce 
at least five members of the EGFR ligand 
family, including AREG, epiregulin, 
heparin-binding EGF-like growth factor, 
betacellulin, and transforming growth 
factor-α  (Coffey et al., 1987; Cook et al., 
1991; Hashimoto et al., 1994; Shirakata 
et al., 2000; Strachan et al., 2001). The 
expression of multiple EGFR ligands in 
keratinocytes raises a question regard-
ing the specific biological role of AREG 
in regulating keratinocyte growth. If 
AREG plays a specific role in regulating 
keratinocyte growth, then what struc-
tural motifs of AREG are responsible for 
this important biological effect? The data 
presented by Stoll et al. (2010) provide 
insights into this complex scenario.
The AREG (also known as 
schwannoma-derived growth factor) 
gene is located on human chromosomal 
band 4q13.3 and yields a 1.4-kb tran-
script composed of six exons that can 
produce a 252–amino acid (aa) trans-
membrane glycoprotein. This polypep-
tide is also known as the pro-form of 
AREG (Pro-AREG). Pro-AREG is com-
posed of multiple domains, including a 
signal sequence (aa 1–19), an N-terminal 
domain (aa 20–101), an EGF-like 
domain (aa 102–184), a membrane stalk 
(aa 185–198), a transmembrane domain 
(aa 199–221), and a cytoplasmic domain 
(aa 222–252).
Transmembrane EGFR ligands such 
as AREG are released from their mem-
brane anchors by metalloproteinases 
and ADAM family proteases; this pro-
cessing adds another layer of regulation 
(Lu et al., 2009; Sternlicht et al., 2005). 
In fact, ADAM17-null mice, to some 
extent, phenocopy EGFR-null mice 
(Sternlicht et al., 2005). As expected, 
proteolysis of AREG results in four mem-
brane-bound and four soluble isoforms 
(Brown et al., 1998). Hypothetically, 
each of these eight isoforms could 
have a unique signaling potential; such 
molecular diversity raises the possibility 
of complex signaling paradigms.
To better understand the role of 
AREG in regulating keratinocyte growth, 
Stoll and colleagues (2010) utilized a 
knockdown approach with lentiviruses 
that express a tetracycline-inducible 
small hairpin RNA (shRNA) targeting 
AREG. Keratinocytes transduced with 
this lentivirus downregulated AREG 
mRNA and cell-associated AREG pro-
tein levels by 83 and 71%, respective-
ly, and shed AREG by more than 95%, 
all in a doxycycline-dependent man-
ner. Previous work by this group has 
shown that AREG antibodies can block 
the autocrine-stimulated ERK phos-
phorylation and keratinocyte prolifera-
tion induced by shed AREG (Kansra et 
al., 2004, 2005). The AREG-dependent 
growth of these keratinocytes was also 
inhibited by metalloproteinase inhibi-
tors and ErbB tyrosine kinase inhibitors, 
